Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
P/B ratio for Arvinas, Inc. (ARVN)
P/B ratio as of 2023: 3.46
According to Arvinas, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.46. At the end of 2022 the company had a P/B ratio of 3.22.
P/B ratio history for Arvinas, Inc. from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.46 |
| 2022 | 3.22 |
| 2021 | 5.25 |
| 2020 | 5.23 |
| 2019 | 5.97 |
| 2018 | 0.89 |
| 2017 | 1353.34 |
| 2016 | 11.94 |